For the Inventor, By the Inventor

Enter assignee name

Waltham, MA, United States of America

Dragonfly Therapeutics, Inc.

USPTO Granted Patents = 14

EPO Patents = 5

Trademarks = 2

Forward Citations = 34

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Ann F Cheung (13 out of 13 patents)

William Haney (12 out of 21 patents)

Asya Grinberg (12 out of 65 patents)

4. Gregory P Chang (12 out of 12 patents)

5. Bianka Prinz (10 out of 58 patents)

6. Bradley M Lunde (10 out of 10 patents)

7. Daniel Fallon (5 out of 5 patents)

8. Nicolai Wagtmann (4 out of 13 patents)

9. Ronnie Wei (4 out of 4 patents)

10. Steven O'Neil (4 out of 4 patents)

11. Jean-Marie Cuillerot (2 out of 8 patents)

12. Eva Gutierrez (2 out of 2 patents)

13. Christopher Ryan Morgan (2 out of 2 patents)

14. Mark DeRose (1 out of 1 patent)

15. Avni Shah (1 out of 1 patent)

14 patents: Sort by Forward Citations

1. 12384851 - Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use (2025-08-12),

2. 12384847 - Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen (2025-08-12),

3. 12378318 - Proteins binding NKG2D, CD16 and a tumor-associated antigen (2025-08-05),

4. 12377144 - Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen (2025-08-05),

5. 12275791 - Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use (2025-04-14),

6. 12264200 - Antibody variable domains targeting the NKG2D receptor (2025-04-01),

7. 12215157 - Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use (2025-02-04),

8. 12157771 - Proteins binding NKG2D, CD16 and CLEC12A (2024-12-03),

9. 12129300 - Antibody variable domains targeting the NKG2D receptor (2024-10-29),

10. 11939384 - Antibody variable domains targeting the NKG2D receptor (2024-03-26),

11. 11884733 - Antibody variable domains targeting the NKG2D receptor (2024-01-30),

12. 11884732 - Proteins binding HER2, NKG2D and CD16 (2024-01-30),

13. 11834506 - Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer (2023-12-05),

14. 11787864 - Heterodimeric Fc-fused proteins (2023-10-17),

Dragonfly Therapeutics is a biotechnology company focused on discovering and developing novel immunotherapies for cancer and other diseases. Their proprietary platform, TriNKETTM, enables the design of precision therapies that harness the body's immune system to target and kill diseased cells. Dragonfly Therapeutics is committed to transforming the treatment landscape for patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

14 Patents

#86 in Waltham, MA

#1,313 in Massachusetts

#21,600 in US

#40,903 in the World

Waltham, MA, United States of America

Dragonfly Therapeutics, Inc.

Forward Citations = 34

21 inventors:

Ann F Cheung (13 out of 13 patents)

William Haney (12 out of 21 patents)

Asya Grinberg (12 out of 65 patents)

4. Gregory P Chang (12 out of 12 patents)

5. Bianka Prinz (10 out of 58 patents)

Please report any incorrect information to support@idiyas.com

Loading…